Karachi, Otsuka Pakistan Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on April 26, 2023 at Karachi. The agenda of the meeting will to consider the Quarterly Accounts for the period ended March 31, 2023.
Further, the company has declared the closed period from April 20, 2023 to April 26, 2023.
Otsuka Pakistan Limited was incorporated in February 1988 and commenced commercial production of Intravenous Solutions in September 1989 at its factory in Hub, Baluchistan. The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan.
Therapeutic Drugs are Otsuka Pakistan’s second line of business; currently consist of Pletaal and Mucosta which are being imported in finished form from Korea. Otsuka Pakistan Limited is the Sole Distributor of Micro port Shanghai Corporation and are importing and selling Micro port products (Stents and Orthopedic products) in Pakistan years. Recently, Otsuka Pakistan has entered into Diagnostic Division and launched Urea Breath Test System (UBiT).
The total numbers of shares are 12,100,000. The Earnings per share is 7.53 in 2020 which was (14.49) in 2019. The Profit after Taxation is 91,066,000 in 2020 which was (175,348,000) in 2019.